At this session, the definition, motivation, and development of polygenic risk scores (PRS) for breast cancer will be presented. The session will also discuss the importance of risk model calibration and the context-specific evaluation of clinical utility (balancing benefits and risks of generating and using genetic risk information in the clinic). Although the session will be focused on breast cancer screening, several general issues in the development and evaluation of PRS for other diseases in other contexts will also be highlighted.
Using Polygenic Risk Scores (PRS) for Breast Cancer to Inform Screening: Model Fit, Calibration, and Utility
Peter Kraft, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Objectives:
- Upon completion, participants will be able to understand the concept and calculation of PRS.
- Upon completion, participants will be able to understand both clinical validity (how it is calibrated) and clinical utility (impact on clinical care) of PRS.
- Upon completion, participants will understand the state of the science regarding PRS for breast cancer and their potential use in risk-stratified screening programs.
Duration: 1.00 hr
Recording Date: November 7, 2019
CME/CMLE credit: 1.00 hr
Last day to purchase course and CE claim credit: December 24, 2022
